Low-dose amitriptyline for irritable bowel syndrome: a qualitative study of patients' and GPs' views and experiences

Irritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second-line treatment, but this is rarely prescribed in primary care. To explore patient...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:British journal of general practice Ročník 75; číslo 755; s. e431
Hlavní autori: Teasdale, Emma J, Everitt, Hazel A, Alderson, Sarah L, Ford, Alexander C, Hanney, James, Chaddock, Matthew, Williamson, Emmajane, Cook, Heather, Farrin, Amanda J, Fernandez, Catherine, Guthrie, Elspeth A, Hartley, Suzanne, Herbert, Amy, Howdon, Daniel, Muir, Delia, Newman, Sonia, Ow, Pei Loo, Ridd, Matthew J, Taylor, Christopher M, Thornton, Ruth, Wright-Hughes, Alexandra, Bishop, Felicity L
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England 01.06.2025
Predmet:
ISSN:1478-5242, 1478-5242
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Irritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second-line treatment, but this is rarely prescribed in primary care. To explore patients' and GPs' views and experiences of using low-dose amitriptyline for IBS. Qualitative interview study with patients and GPs in England, nested within the ATLANTIS trial of low-dose amitriptyline versus placebo (ISRCTN48075063). Semi-structured telephone interviews were conducted with 42 patients at 6 months post-randomisation, with 19 patients again at 12 months post-randomisation, and with 16 GPs between April 2020 and March 2022. Reflexive thematic analysis was used to analyse patient and GP data separately, then together, to identify unique and cross-cutting themes. We found concerns about amitriptyline being an antidepressant, medicalising IBS, and side effects. Perceived benefits included the low and flexible dose, ease of treatment, and familiarity of amitriptyline and its potential to offer benefits beyond IBS symptom relief. These concerns and perceived benefits were expressed in the context of desire for a novel approach to IBS: GPs were keen to offer more options for IBS and patients sought a cure for their symptoms. Patients and GPs felt that the potential benefits of trying low-dose amitriptyline for IBS outweighed their concerns. When offering low-dose amitriptyline for IBS, GPs could address patient concerns about taking an antidepressant for IBS, highlighting the low and flexible dosage, and other potential benefits of amitriptyline such as improved sleep.
AbstractList Irritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second-line treatment, but this is rarely prescribed in primary care.BACKGROUNDIrritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second-line treatment, but this is rarely prescribed in primary care.To explore patients' and GPs' views and experiences of using low-dose amitriptyline for IBS.AIMTo explore patients' and GPs' views and experiences of using low-dose amitriptyline for IBS.Qualitative interview study with patients and GPs in England, nested within the ATLANTIS trial of low-dose amitriptyline versus placebo (ISRCTN48075063).DESIGN AND SETTINGQualitative interview study with patients and GPs in England, nested within the ATLANTIS trial of low-dose amitriptyline versus placebo (ISRCTN48075063).Semi-structured telephone interviews were conducted with 42 patients at 6 months post-randomisation, with 19 patients again at 12 months post-randomisation, and with 16 GPs between April 2020 and March 2022. Reflexive thematic analysis was used to analyse patient and GP data separately, then together, to identify unique and cross-cutting themes.METHODSemi-structured telephone interviews were conducted with 42 patients at 6 months post-randomisation, with 19 patients again at 12 months post-randomisation, and with 16 GPs between April 2020 and March 2022. Reflexive thematic analysis was used to analyse patient and GP data separately, then together, to identify unique and cross-cutting themes.We found concerns about amitriptyline being an antidepressant, medicalising IBS, and side effects. Perceived benefits included the low and flexible dose, ease of treatment, and familiarity of amitriptyline and its potential to offer benefits beyond IBS symptom relief. These concerns and perceived benefits were expressed in the context of desire for a novel approach to IBS: GPs were keen to offer more options for IBS and patients sought a cure for their symptoms.RESULTSWe found concerns about amitriptyline being an antidepressant, medicalising IBS, and side effects. Perceived benefits included the low and flexible dose, ease of treatment, and familiarity of amitriptyline and its potential to offer benefits beyond IBS symptom relief. These concerns and perceived benefits were expressed in the context of desire for a novel approach to IBS: GPs were keen to offer more options for IBS and patients sought a cure for their symptoms.Patients and GPs felt that the potential benefits of trying low-dose amitriptyline for IBS outweighed their concerns. When offering low-dose amitriptyline for IBS, GPs could address patient concerns about taking an antidepressant for IBS, highlighting the low and flexible dosage, and other potential benefits of amitriptyline such as improved sleep.CONCLUSIONPatients and GPs felt that the potential benefits of trying low-dose amitriptyline for IBS outweighed their concerns. When offering low-dose amitriptyline for IBS, GPs could address patient concerns about taking an antidepressant for IBS, highlighting the low and flexible dosage, and other potential benefits of amitriptyline such as improved sleep.
Irritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second-line treatment, but this is rarely prescribed in primary care. To explore patients' and GPs' views and experiences of using low-dose amitriptyline for IBS. Qualitative interview study with patients and GPs in England, nested within the ATLANTIS trial of low-dose amitriptyline versus placebo (ISRCTN48075063). Semi-structured telephone interviews were conducted with 42 patients at 6 months post-randomisation, with 19 patients again at 12 months post-randomisation, and with 16 GPs between April 2020 and March 2022. Reflexive thematic analysis was used to analyse patient and GP data separately, then together, to identify unique and cross-cutting themes. We found concerns about amitriptyline being an antidepressant, medicalising IBS, and side effects. Perceived benefits included the low and flexible dose, ease of treatment, and familiarity of amitriptyline and its potential to offer benefits beyond IBS symptom relief. These concerns and perceived benefits were expressed in the context of desire for a novel approach to IBS: GPs were keen to offer more options for IBS and patients sought a cure for their symptoms. Patients and GPs felt that the potential benefits of trying low-dose amitriptyline for IBS outweighed their concerns. When offering low-dose amitriptyline for IBS, GPs could address patient concerns about taking an antidepressant for IBS, highlighting the low and flexible dosage, and other potential benefits of amitriptyline such as improved sleep.
Author Ridd, Matthew J
Everitt, Hazel A
Fernandez, Catherine
Newman, Sonia
Ow, Pei Loo
Chaddock, Matthew
Hartley, Suzanne
Howdon, Daniel
Alderson, Sarah L
Muir, Delia
Teasdale, Emma J
Cook, Heather
Thornton, Ruth
Ford, Alexander C
Bishop, Felicity L
Hanney, James
Farrin, Amanda J
Guthrie, Elspeth A
Wright-Hughes, Alexandra
Herbert, Amy
Taylor, Christopher M
Williamson, Emmajane
Author_xml – sequence: 1
  givenname: Emma J
  orcidid: 0000-0001-9147-193X
  surname: Teasdale
  fullname: Teasdale, Emma J
  email: e.j.teasdale@soton.ac.uk
  organization: Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton e.j.teasdale@soton.ac.uk
– sequence: 2
  givenname: Hazel A
  orcidid: 0000-0001-7362-8403
  surname: Everitt
  fullname: Everitt, Hazel A
  organization: Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton
– sequence: 3
  givenname: Sarah L
  orcidid: 0000-0002-5418-0495
  surname: Alderson
  fullname: Alderson, Sarah L
  organization: Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds
– sequence: 4
  givenname: Alexander C
  orcidid: 0000-0001-6371-4359
  surname: Ford
  fullname: Ford, Alexander C
  organization: Leeds Gastroenterology Institute, St James's University Hospital, Leeds; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds
– sequence: 5
  givenname: James
  surname: Hanney
  fullname: Hanney, James
  organization: Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton
– sequence: 6
  givenname: Matthew
  surname: Chaddock
  fullname: Chaddock, Matthew
  organization: Let's Cure IBS (IBS support group), Leeds
– sequence: 7
  givenname: Emmajane
  surname: Williamson
  fullname: Williamson, Emmajane
  organization: Let's Cure IBS (IBS support group), Leeds
– sequence: 8
  givenname: Heather
  surname: Cook
  fullname: Cook, Heather
  organization: Exeter Clinical Trials Unit, University of Exeter, Exeter
– sequence: 9
  givenname: Amanda J
  orcidid: 0000-0002-2876-0584
  surname: Farrin
  fullname: Farrin, Amanda J
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 10
  givenname: Catherine
  surname: Fernandez
  fullname: Fernandez, Catherine
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 11
  givenname: Elspeth A
  orcidid: 0000-0002-5834-6616
  surname: Guthrie
  fullname: Guthrie, Elspeth A
  organization: Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds
– sequence: 12
  givenname: Suzanne
  surname: Hartley
  fullname: Hartley, Suzanne
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 13
  givenname: Amy
  orcidid: 0009-0008-6109-6006
  surname: Herbert
  fullname: Herbert, Amy
  organization: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol
– sequence: 14
  givenname: Daniel
  surname: Howdon
  fullname: Howdon, Daniel
  organization: Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds
– sequence: 15
  givenname: Delia
  surname: Muir
  fullname: Muir, Delia
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 16
  givenname: Sonia
  surname: Newman
  fullname: Newman, Sonia
  organization: Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton
– sequence: 17
  givenname: Pei Loo
  surname: Ow
  fullname: Ow, Pei Loo
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 18
  givenname: Matthew J
  orcidid: 0000-0002-7954-8823
  surname: Ridd
  fullname: Ridd, Matthew J
  organization: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol
– sequence: 19
  givenname: Christopher M
  surname: Taylor
  fullname: Taylor, Christopher M
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 20
  givenname: Ruth
  surname: Thornton
  fullname: Thornton, Ruth
  organization: Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton
– sequence: 21
  givenname: Alexandra
  orcidid: 0000-0001-8839-6756
  surname: Wright-Hughes
  fullname: Wright-Hughes, Alexandra
  organization: Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds
– sequence: 22
  givenname: Felicity L
  orcidid: 0000-0002-8737-6662
  surname: Bishop
  fullname: Bishop, Felicity L
  organization: Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39191441$$D View this record in MEDLINE/PubMed
BookMark eNpNkD1PwzAYhC1URD9gZUTeYEnxV9KYDSoooEp0gLmy4zeSURKnttOSf08ERWK6O92jG26KRo1rAKFLSuacS3n78LrazBlhYk444SdoQsUiT1Im2OifH6NpCJ-EMJZRcobGXFJJhaATFNfukBgXAKvaRm_b2Fe2AVw6j633NipdAdbuABUOfWO8q-EOK7zrVDWU0e4Bh9iZHrsSt0OGJoZrrBqDV5vB7C0cwk-Erxb8UBcQztFpqaoAF0edoY-nx_flc7J-W70s79dJIRiNCSupUkrnSmshSWZEniphUl0IAaU0XOcARSpLzXlGdMaYojIdwLws8pRmnM3Qze9u692ugxC3tQ0FVJVqwHVhy4lcDCSn2YBeHdFO12C2rbe18v327yn2DQ45bfE
CitedBy_id crossref_primary_10_1136_gutjnl_2024_334490
crossref_primary_10_1111_jgh_16858
crossref_primary_10_1038_s41575_025_01065_9
crossref_primary_10_3399_BJGP_2025_0190
ContentType Journal Article
Copyright The Authors.
Copyright_xml – notice: The Authors.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3399/BJGP.2024.0303
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1478-5242
ExternalDocumentID 39191441
Genre Journal Article
GeographicLocations England
GeographicLocations_xml – name: England
GroupedDBID ---
.GJ
23N
2WC
53G
5GY
5RE
5VS
6PF
AAFWJ
AAWTL
ABOCM
ABSQV
ACDUE
ADBBV
ADDZX
ADMOG
AENEX
AFHIN
AFPMT
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBS
ECM
EIF
EJD
EMOBN
F5P
GX1
H13
HYE
K-O
KQ8
L7B
NPM
P2P
R0Z
RHI
RPM
SJN
SV3
TR2
WOQ
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c421t-2f1aaab8abb4906d485a4d5bc44ef9d3b8eec59fb3360b622a1959068fc851632
IEDL.DBID 7X8
ISICitedReferencesCount 4
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001444502400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1478-5242
IngestDate Thu Oct 02 10:33:17 EDT 2025
Mon Jul 21 05:56:00 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 755
Keywords amitriptyline
primary care
qualitative research
irritable bowel syndrome
patient experience
Language English
License The Authors.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c421t-2f1aaab8abb4906d485a4d5bc44ef9d3b8eec59fb3360b622a1959068fc851632
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-7362-8403
0000-0002-2876-0584
0000-0001-8839-6756
0000-0002-5834-6616
0000-0001-9147-193X
0000-0002-5418-0495
0000-0001-6371-4359
0009-0008-6109-6006
0000-0002-8737-6662
0000-0002-7954-8823
OpenAccessLink https://bjgp.org/content/bjgp/early/2024/08/27/BJGP.2024.0303.full.pdf
PMID 39191441
PQID 3097851316
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3097851316
pubmed_primary_39191441
PublicationCentury 2000
PublicationDate 2025-06-01
PublicationDateYYYYMMDD 2025-06-01
PublicationDate_xml – month: 06
  year: 2025
  text: 2025-06-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle British journal of general practice
PublicationTitleAlternate Br J Gen Pract
PublicationYear 2025
SSID ssj0022610
Score 2.4589903
Snippet Irritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use....
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage e431
SubjectTerms Adult
Aged
Amitriptyline - administration & dosage
Amitriptyline - therapeutic use
Antidepressive Agents, Tricyclic - administration & dosage
Attitude of Health Personnel
England
Female
General Practitioners - psychology
Humans
Irritable Bowel Syndrome - drug therapy
Irritable Bowel Syndrome - psychology
Male
Middle Aged
Primary Health Care
Qualitative Research
Quality of Life
Title Low-dose amitriptyline for irritable bowel syndrome: a qualitative study of patients' and GPs' views and experiences
URI https://www.ncbi.nlm.nih.gov/pubmed/39191441
https://www.proquest.com/docview/3097851316
Volume 75
WOSCitedRecordID wos001444502400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF58IV58P-qLFQRPsdlH0qwXUdGK2NKDQm9ln1CoiZpq8d87u0nrSRC8hM0hsMxMZr6Z2f0GoVOwAkWJYqABwiKuHYuEaJGIWcYTaxKpVByGTbS63azfF7264FbWxyqnPjE4alNoXyNvMn_hICGMpJevb5GfGuW7q_UIjXm0yADK-CNdrf6siwDIomIj4JApJRCLKtJGBjG5ef3Q7kF2SPk5WDn7HV6GMHO39t8NrqPVGmDiq8oiNtCczTfRcqduoW-h8WMxiUxRWixfhmPvMr480sQAXvHw3ZcK1MhiVUzsCE_pDC6wxNXty0ATjgMnLS4crllZyzMsc4PbPVgEctPwamcsyuU2er67fbq5j-rRC5HmlIwj6oiUUmWgKi7i1PAskdwkSnNunTBMZdbqRDjFWBqrlFLpSWriNHMaZJAyuoMW8iK3ewirzHBFRBZrSIAhHxapo6lRysWspU1sG-hkKs8BmLbvV8jcFh_l4EeiDbRbKWXwWnFwDJjwxHSc7P_h6wO0Qv3U3lA7OUSLDn5se4SW9Od4WL4fB5uBZ7fX-QZIrsyh
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-dose+amitriptyline+for+irritable+bowel+syndrome%3A+a+qualitative+study+of+patients%27+and+GPs%27+views+and+experiences&rft.jtitle=British+journal+of+general+practice&rft.au=Teasdale%2C+Emma+J&rft.au=Everitt%2C+Hazel+A&rft.au=Alderson%2C+Sarah+L&rft.au=d%2C+Alexander+C&rft.date=2025-06-01&rft.issn=1478-5242&rft.eissn=1478-5242&rft_id=info:doi/10.3399%2FBJGP.2024.0303&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-5242&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-5242&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-5242&client=summon